Literature DB >> 14685691

Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells.

S M de la Monte1, G J Chen, E Rivera, J R Wands.   

Abstract

In Alzheimer's disease (AD), neuronal thread protein (NTP) accumulates in cortical neurons and colocalizes with phospho- tau-immunoreactive cytoskeletal lesions that correlate with dementia. To generate additional information about the potential role of NTP in AD, we characterized its expression and regulation in human SH-Sy5y neuronal cells. Quantitative real-time reverse transcription-polymerase chain reactin and Western blot analysis demonstrated prominent insulin, moderate insulin-like growth factor, type 1 (IGF-1) and minimal nerve growth factor stimulation of NTP expression. In addition, NTP protein was more stable and it progressively accumulated in cells that were stimulated with insulin for 24 or 48 h. Metabolic labeling and phospho-amino acid analysis demonstrated phosphorylation of NTP on Serine residues, 30-60 min after insulin or IGF-1 stimulation, when glycogen synthase kinase 3beta (GSK-3beta) activity would no longer have been suppressed. Kinase inhibitor and in vitro phosphorylation studies demonstrated a role for GSK-3beta in the positive regulation of NTP expression and phosphorylation. Coimmunoprecipitation studies demonstrated physical interactions between NTP and tau or microtubule-associated protein 1b (MAP-1b), and ubiquitin immunoreactivity in NTP immunoprecipitates. In summary, these studies showed that (i) NTP expression is regulated at the level of transcription by insulin and IGF-1 stimulation; (ii) NTP is phosphorylated by GSK-3beta; (iii) NTP can physically interact with tau and MAP-1b and (iv) NTP-MAP complexes are ubiquitinated. The results suggest a functional role for NTP in relation to the turnover or processing of neuronal cytoskeletal proteins, attributes that may be modulated by insulin/IGF-1-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685691     DOI: 10.1007/s00018-003-3305-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  26 in total

1.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  The JUPITER trial: results, controversies, and implications for prevention.

Authors:  Paul M Ridker
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-05

3.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

Authors:  W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

4.  Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.

Authors:  Claire Arnaud; Fabienne Burger; Sabine Steffens; Niels R Veillard; Tuan Huy Nguyen; Didier Trono; François Mach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-24       Impact factor: 8.311

5.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 6.  C-reactive protein: risk marker or mediator in atherothrombosis?

Authors:  Ishwarlal Jialal; Sridevi Devaraj; Senthil K Venugopal
Journal:  Hypertension       Date:  2004-05-17       Impact factor: 10.190

7.  Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States.

Authors:  Earl S Ford; Chaoyang Li; Guixiang Zhao; Ali H Mokdad
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

8.  National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease.

Authors:  Gary L Myers; Robert H M Christenson; Mary Cushman; Christie M Ballantyne; Gerald R Cooper; Christine M Pfeiffer; Scott M Grundy; Darwin R Labarthe; Daniel Levy; Nader Rifai; Peter W F Wilson
Journal:  Clin Chem       Date:  2008-12-23       Impact factor: 8.327

9.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Authors:  Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker
Journal:  N Engl J Med       Date:  2009-03-29       Impact factor: 91.245

10.  C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.

Authors:  Wolfgang Koenig; Hannelore Löwel; Jens Baumert; Christa Meisinger
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

View more
  17 in total

Review 1.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 2.  Role of central nervous system insulin resistance in fetal alcohol spectrum disorders.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Popul Ther Clin Pharmacol       Date:  2010-10-26

3.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

Review 4.  The Placenta as a Target for Alcohol During Pregnancy: The Close Relation with IGFs Signaling Pathway.

Authors:  Inma Castilla-Cortázar; Fabiola Castorena-Torres; Irene Martín-Estal
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 5.  Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

Authors:  Suzanne M de la Monte
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-28       Impact factor: 4.600

Review 6.  Linking insulin with Alzheimer's disease: emergence as type III diabetes.

Authors:  Sara Ahmed; Zahra Mahmood; Saadia Zahid
Journal:  Neurol Sci       Date:  2015-08-07       Impact factor: 3.307

Review 7.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

Review 8.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

9.  Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.

Authors:  Nan Zhang; Liling Zhang; Yan Li; Marc L Gordon; Li Cai; Ying Wang; Mengya Xing; Yan Cheng
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease.

Authors:  Somang Kang; Yong Ho Lee; Jong Eun Lee
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.